Asymmetry Capital Management as of Sept. 30, 2015
Portfolio Holdings for Asymmetry Capital Management
Asymmetry Capital Management holds 22 positions in its portfolio as reported in the September 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| DaVita (DVA) | 9.1 | $4.1M | 56k | 72.32 | |
| Edwards Lifesciences (EW) | 8.7 | $3.9M | 28k | 142.16 | |
| Quest Diagnostics Incorporated (DGX) | 8.3 | $3.7M | 61k | 61.47 | |
| Amicus Therapeutics (FOLD) | 7.3 | $3.3M | 233k | 13.99 | |
| Nevro (NVRO) | 6.4 | $2.9M | 62k | 46.38 | |
| Centene Corporation (CNC) | 6.1 | $2.8M | 51k | 54.23 | |
| Teva Pharmaceutical Industries (TEVA) | 6.0 | $2.7M | 48k | 56.46 | |
| Stryker Corporation (SYK) | 5.8 | $2.6M | 28k | 94.09 | |
| MiMedx (MDXG) | 4.9 | $2.2M | 230k | 9.65 | |
| Neurocrine Biosciences (NBIX) | 4.4 | $2.0M | 50k | 39.80 | |
| Endo Pharmaceuticals | 4.1 | $1.8M | 27k | 69.29 | |
| Bristol Myers Squibb (BMY) | 3.9 | $1.8M | 30k | 59.20 | |
| Aerie Pharmaceuticals | 3.4 | $1.5M | 86k | 17.74 | |
| Clovis Oncology | 3.4 | $1.5M | 17k | 91.93 | |
| Sagent Pharmaceuticals | 3.1 | $1.4M | 92k | 15.33 | |
| Impax Laboratories | 3.0 | $1.3M | 38k | 35.22 | |
| Vanda Pharmaceuticals (VNDA) | 3.0 | $1.3M | 119k | 11.28 | |
| XenoPort | 2.9 | $1.3M | 368k | 3.47 | |
| Anacor Pharmaceuticals | 2.5 | $1.1M | 9.3k | 117.66 | |
| Synergy Pharmaceuticals | 2.4 | $1.1M | 203k | 5.30 | |
| Penumbra (PEN) | 0.9 | $400k | 10k | 40.08 | |
| Epirus Biopharmaceuticals In (EPRSQ) | 0.4 | $189k | 43k | 4.42 |
